+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
169.4300
1.8595
-.4032
.1233
.8525
2.3875
Low
75.8196
5.4205
No
No
No
No
No
No
0.0
Yes
No
No
No
Ganoderma (Ganoderma spp.), as a highly representative medicinal fungus in traditional Chinese medicine, has long attracted significant attention from the scientific community due to its diverse biological activities and broad clinical applications. Ganoderma contains abundant triterpenoid compounds, especially lanostane-type triterpenoids, which are considered one of the main active components for their pharmacological effects. 20-Hydroxyganoderic acid G (CAS No.: 400604-12-8), a typical lanolinese triterpenoid compound isolated from the ethanol extract of Ganoderma curtisii fruiting bodies, has attracted widespread attention in recent years due to its potential role in regulating neuroinflammation.
Neuroinflammation is a key link in the pathogenesis of various neurological diseases (such as Alzheimer's, Parkinson's, multiple sclerosis, etc.), and microglia, as the innate immune cells of the central nervous system, have activated status that directly affects the progression of neuroinflammation. 20-Hydroxygazhid acid G can inhibit BV-2 microglia activated by lipopolysaccharides (LPS), demonstrating significant anti-inflammatory activity, with an IC50 of 21.33 μM, indicating significant research value and application potential in neuroimmune regulation.
This paper will systematically review the chemical structure and physicochemical properties, plant origin and extraction methods, pharmacological activity and mechanism of action of 20-hydroxygazhi acid G, druggability evaluation and pharmacokinetic characteristics, combined with current clinical application prospects, aiming to provide scientific basis and theoretical support for in-depth research and drug development of this natural product.
20-Hydroxygaderma acid G belongs to the lanosterane triterpene compound, with the molecular formula C30H44O10 and a molecular weight of 548.6730. Its structure is based on the typical lanosterane skeletone and contains multiple hydroxyl and carboxyl functional groups, giving it strong polarity and biological activity. The introduction of a 20-position hydroxyl group in the molecular structure is a key feature of its naming, and this hydroxyl group may have a significant impact on its biological activity.
In terms of physicochemical properties, the LogP value of 20-hydroxygazhi acid G is 1.8595, indicating moderate lipid solubility, which facilitates cell membrane penetration but is not overly hydrophobic and would affect bioavailability. The polar surface area (TPSA) is 169.43 Ų, and a higher TPSA value usually indicates stronger molecular polarity, which may limit its ability to cross the blood-brain barrier, which aligns with its low blood-brain barrier permeability assessment. Water solubility was 0.1233 (unit unclear, but can be inferred at the mg/mL or mol/L level), indicating low water solubility and suggesting that appropriate solubility improvement strategies may be needed in drug formulation design.
In terms of safety, 20-hydroxyazhid acid G does not inhibit hERG channels, reducing the potential risk of cardiotoxicity; The Ames test result was 0.0, indicating no significant genotoxicity and a solid safety foundation.
20-Hydroxygaderma acid G mainly originates from the fruiting body of the Ganoderma curtisii fungus. Ganoderma is a wood decay fungus from the Polypore family, widely distributed in temperate and subtropical regions of Asia. It is an important medicinal material in traditional Chinese medicine for regulating immunity, fighting tumors, fighting inflammation, and delaying aging.
The extraction of 20-hydroxygaderma acid G typically uses ethanol (EtOH) as the solvent, extracted from dried Ganoderma lucidum fruiting bodies. The ethanol extraction method can effectively dissolve triterpenoids in Ganoderma lucidum, followed by liquid-liquid separation, column chromatography (such as silica gel columns, C18 reversed-phase columns), and high-performance liquid chromatography (HPLC) to obtain pure 20-hydroxyGanoderma acid G.
In recent years, with advances in extraction technology, green and efficient methods such as ultrasound-assisted extraction and microwave-assisted extraction have also been applied to the extraction of Ganoderma triterpenes, significantly improving extraction efficiency and purity, and providing technical support for the large-scale preparation of 20-hydroxyGathyrium acid G. In addition, structural identification mainly relies on modern analytical methods such as nuclear magnetic resonance (NMR), mass spectrometry (MS), and infrared spectroscopy (IR) to ensure the accuracy and purity of compounds.
Pharmacological activity studies of 20-hydroxygazhi acid G have mainly focused on its anti-inflammatory and immunomodulatory effects, especially in models of neuroinflammation-related diseases. Using LPS-activated BV-2 microglia as an in vitro model, 20-hydroxygazhid acid G exhibited significant inhibitory effects, with an IC50 of 21.33 μM, indicating its effective inhibition of microglial overactivation and reduction of neuroinflammatory responses.
Microglia, as immune effector cells of the central nervous system, have activation levels closely related to the pathological progression of various neurodegenerative diseases. 20-Hydroxygazhi acid G regulates the release of inflammatory mediators in microglia, reduces the expression of pro-inflammatory cytokines (such as TNF-α, IL-1β, IL-6), alleviates neuroinflammatory damage, and demonstrates good neuroprotective potential.
In addition, 20-hydroxygazhi acid G also has potential application value in immune regulation. Relevant studies have shown that this compound can influence the activity of various immune-related targets, regulate the functional status of immune cells, and promote the maintenance of immune homeostasis. Although there are currently few reports on its anti-tumor and antioxidant pharmacological activities, based on its structural characteristics and the activity of similar Ganoderma triterpenes, future research is expected to further expand its pharmacological spectrum of effects.
The mechanism of action of 20-hydroxygazhi acid G mainly involves regulation of immune signaling pathways, especially targeting key molecular targets in LPS-induced inflammatory responses. As a component of the cell wall of Gram-negative bacteria, LPS activates the downstream inflammatory signaling cascade by activating Toll-like receptor 4 (TLR4), leading to the activation of transcription factors such as nuclear factor κB (NF-κB), thereby promoting the expression of pro-inflammatory cytokines.
Research shows that 20-hydroxygaderma acid G can inhibit TLR4 activation, thereby downregulating the activity of the NF-κB (NFKB1) signaling pathway and reducing the release of pro-inflammatory factors. Additionally, this compound affects the STAT3 and STAT4 signaling pathways, which play key roles in immune cell differentiation and functional regulation. By modulating STAT3/STAT4,20-hydroxygazhi acid G, it helps balance pro-inflammatory and anti-inflammatory responses and promotes immune homeostasis.
At the cytokine level, 20-hydroxygazhi acid G regulates the expression of several key factors, including IL-2, IL-10, IFN-γ (IFNG), TGF-β1 (TGFB1), and others, which play important roles in immune regulation and inflammatory responses. In particular, upregulation of IL-10 and FOXP3 suggests that this compound may promote regulatory T cell (Treg) function, enhance immunosuppressive effects, and further suppress excessive inflammation.
Additionally, the regulatory effect of 20-hydroxygazhi acid G on CTLA4 also suggests its potential value in immune checkpoint regulation, potentially affecting T cell activation and immune tolerance mechanisms. The integrated regulation of these molecular targets forms the molecular basis for 20-hydroxygazhi acid G to exert its immunomodulatory and anti-inflammatory effects.
Druggability evaluation is a crucial step in the development of natural product drugs. The molecular weight of 20-hydroxygazhid acid G is 548.6730, slightly above the upper limit of 500 Da recommended by Lipinski's rules, but its LogP value of 1.8595 is moderate, which is beneficial for cell membrane penetration. A higher TPSA (169.43 Ų) and lower water solubility (0.1233) suggest certain limitations in oral absorption and blood-brain barrier penetration.
The low permeability of the blood-brain barrier may limit its ability to directly act on the central nervous system, but therapeutic strategies targeting peripheral immune cells or the meningeal immune environment may offer advantages to avoid potential central nervous system toxicity.
In terms of safety, 20-hydroxygazhi acid G does not inhibit hERG channels, reducing the risk of cardiotoxicity; The Ames test was negative, indicating no significant genotoxicity and promising safety potential.
Regarding pharmacokinetics, there is currently a lack of systematic in vivo data on metabolism, distribution, excretion, and bioavailability. Given its high molecular weight and polarity, future research should focus on its in vivo stability, metabolic pathways, and formulation improvement strategies to enhance its bioavailability and therapeutic efficacy.
As a natural triterpene compound with significant immunomodulatory and anti-inflammatory activities, 20-hydroxygazhi acid G shows broad application prospects in the treatment of neuroinflammation-related diseases. Its inhibitory effect on LPS-activated microglia offers new ideas for adjunctive treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis.
Additionally, 20-hydroxygazhid acid G regulates multiple immune-related targets, suggesting its potential application value in autoimmune diseases, chronic inflammatory diseases, and immune dysregulation states. Combined with Ganoderma's traditional immunomodulatory effects, this compound is expected to become an important candidate for natural drug development.
In the future, it is necessary to strengthen in vivo pharmacodynamics and safety evaluation of 20-hydroxygazhi acid G, conduct animal models and preclinical studies, and clarify its pharmacokinetic characteristics and dose-effect relationships. At the same time, optimizing formulation technology based on its physicochemical properties and improving bioavailability and targeting will be key to promoting its clinical translation.
The multi-target, multi-pathway mechanism of action provides a theoretical basis for the combination therapy and multi-disease treatment of 20-hydroxygazhi acid G. In the future, its synergistic effects with existing anti-inflammatory and immunomodulatory drugs can be explored, expanding its clinical application scope.
20-Hydroxygazhi acid G, as an important natural product of the lanosterane triterpene in Ganoderma lucidum, has become a hot topic in research on neuroinflammation and related immune diseases due to its unique chemical structure and significant immunomodulatory and anti-inflammatory activities. By regulating key signaling pathways such as TLR4, NF-κB, and STAT3/4, it influences the expression of various cytokines, demonstrating a complex yet effective multi-target mechanism.
Although research on its pharmacokinetics and clinical applications is still in its early stages, its good safety profile and potential therapeutic value lay a solid foundation for future drug development. With continuous advances in extraction and purification technologies and drug design strategies, 20-hydroxygazhi acid G is expected to become a major breakthrough in the field of natural product pharmacology, providing novel drug candidates for the treatment of neuroinflammation and immunomodulatory-related diseases.
Future research should focus on deeply elucidating its molecular mechanisms, optimizing drug formulations, conducting systematic in vitro and in vitro evaluations, and preclinical studies, to promote 20-hydroxygazhi acid G from the laboratory to clinical application, benefiting a wide range of patients.
Shenshuai
Wenjing
Hedandan
